Documented batches Public COA verification Research use only Quality standards
Primal Platform
← Back to all peptide profiles
Cyclic peptide Approval and post-marketing data Human data available

Peptide database · P-020

Bremelanotide

PT-141; Vyleesi

Bremelanotide is a cyclic melanocortin peptide analogue with a specific U.S. approval for a defined indication.

01

Molecular profile

Molecular profile

Molecule class
Cyclic peptide
Origin
Synthetic analogue
Primary target system
Melanocortinrezeptoren, insbesondere MC4R
Development stage
Authorised active substance
Structure note

Zyklisches Heptapeptid und Melanocortinrezeptor-Agonist.

02

Mechanism and signalling

Mechanism and signalling

Central melanocortin-receptor activation affects neuroendocrine and motivational networks; contributions from individual receptor subtypes are complex.

03

Scientific classification

Scientific classification

This profile maps Bremelanotid to the research areas reproductive, neuro. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.

Reproductive and social neuroendocrinology

Peptide signals related to reproductive axes, social behaviour and sexual function.

Neuroactive research

Neuropeptides and analogues in models of neuronal signalling, stress and pain.

04

Evidence base

Approval and post-marketing data

PreclinicalEarly human dataClinical dataPhase IIPhase IIIApproval and post-marketing data

Approval trials and prescribing information support the specific U.S. indication. They do not support unlicensed products or other uses.

05

Regulatory status

Specifically approved in the U.S.

Specifically approved in the U.S.

The substance has a specific U.S. approval. This does not constitute general authorisation in Germany or the European Union, nor approval of unlicensed products.

06

Safety and use notice

No dosing or administration recommendation

The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.

07

Sources and registries

Sources and registries